Luye Pharma Group (FRA:LUP) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:LUP Luye Pharma Group Ltd FRA:LUP
52 GF Score
Price €0.24
GF Value €0.35
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Luye Pharma Group FFO per Share?

FFO per Share only applies to REITs.

FRA:LUP
52GF Score
Luye Pharma Group Ltd FRA:LUP
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Luye Pharma Group (FRA:LUP) Overvalued in 2026?

Based on GuruFocus' analysis, Luye Pharma Group stock appears to be undervalued. The current stock price of €0.24 is trading 30.3% below its estimated GF Value™ of €0.35. GuruFocus considers Luye Pharma Group to be Possible Value Trap.

Key valuation signals for FRA:LUP:

  • FFO per Share:
  • GF Value™: €0.35 vs. price of €0.24 (30.3% below fair value)
  • GF Score™: 52/100 with 5 warning signs

No single metric tells the full story. See the FRA:LUP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Luye Pharma Group Business Description

Other Exchanges LYPHF:USA02186:Hong Kong
Address Hongqiao Road 1438, 22nd Floor, Gubei International Fortune Center II, Changning District, Shanghai, CHN
Luye Pharma Group Ltd is a China-based drug manufacturer that focuses on development, production, marketing and sale of pharmaceutical products. The company develops drugs related to diagnosing and treating cancer, the cardiovascular system, the alimentary tract, and the central nervous system. The company develops drugs for world-wide use in Asia, Europe, and the United States. The Group organizes its business segments by type of products. Oncology drugs, which derives maximum revenue; Cardiovascular system drugs; Alimentary tract and metabolism drugs; Central nervous system drugs; and others. Geographically, the group derives maximum revenue from Chinese Mainland, while it also has its presence in Asia (other than the Chinese mainland), European Union, and Other countries.
52GF Score

Get the complete analysis for FRA:LUP

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.24
Price
€0.35
GF Value